Header Logo

Connection

ROY F CHEMALY to Cytomegalovirus Infections

Back to Details
This is a "connection" page, showing publications ROY F CHEMALY has written about Cytomegalovirus Infections.
ROY F CHEMALY
Connection Strength
10.758
Cytomegalovirus Infections
  1. Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium. Clin Microbiol Infect. 2023 Jan; 29(1):44-50.
    View in: PubMed
    Score: 0.623
  2. Cytomegalovirus (CMV) Cell-Mediated Immunity and CMV Infection After Allogeneic Hematopoietic Cell Transplantation: The REACT Study. Clin Infect Dis. 2020 12 03; 71(9):2365-2374.
    View in: PubMed
    Score: 0.557
  3. Disseminated cytomegalovirus infection with bilateral adrenal pseudotumors masquerading as recurrent hematologic malignancy. Infection. 2020 Jun; 48(3):477-481.
    View in: PubMed
    Score: 0.529
  4. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr Opin Infect Dis. 2019 12; 32(6):565-574.
    View in: PubMed
    Score: 0.519
  5. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020 01; 92(1):86-95.
    View in: PubMed
    Score: 0.511
  6. Reply to Gim?nez et al. J Infect Dis. 2019 04 16; 219(9):1512-1513.
    View in: PubMed
    Score: 0.497
  7. Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials. Clin Infect Dis. 2019 04 08; 68(8):1420-1426.
    View in: PubMed
    Score: 0.497
  8. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2019 02 23; 219(6):898-907.
    View in: PubMed
    Score: 0.492
  9. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Rev Clin Pharmacol. 2018 Oct; 11(10):931-941.
    View in: PubMed
    Score: 0.478
  10. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016 12 08; 128(23):2624-2636.
    View in: PubMed
    Score: 0.419
  11. Adjuvant and salvage therapy with leflunomide for recalcitrant cytomegalovirus infections in hematopoietic cell transplantation recipients: A case series. Antiviral Res. 2016 11; 135:91-96.
    View in: PubMed
    Score: 0.415
  12. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Res. 2016 10; 134:58-62.
    View in: PubMed
    Score: 0.414
  13. Utility of the Enzyme-Linked Immunospot Interferon-?-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients. J Infect Dis. 2016 Jun 01; 213(11):1701-7.
    View in: PubMed
    Score: 0.399
  14. CMV prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 08 07; 371(6):576-7.
    View in: PubMed
    Score: 0.359
  15. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014 Jan 01; 342(1):1-8.
    View in: PubMed
    Score: 0.338
  16. Fatal cytomegalovirus pneumonia in patients with haematological malignancies: an autopsy-based case-control study. Clin Microbiol Infect. 2008 Dec; 14(12):1160-6.
    View in: PubMed
    Score: 0.242
  17. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin Lymphoma Myeloma. 2006 Mar; 6(5):393-8.
    View in: PubMed
    Score: 0.200
  18. Cytomegalovirus pneumonia in patients with lymphoma. Cancer. 2005 Sep 15; 104(6):1213-20.
    View in: PubMed
    Score: 0.194
  19. Gastrointestinal cytomegalovirus disease in patients with cancer: a two decade experience in a tertiary care cancer center. Eur J Cancer. 2005 Oct; 41(15):2268-79.
    View in: PubMed
    Score: 0.194
  20. Clinical utility of cytomegalovirus viral load in bronchoalveolar lavage in lung transplant recipients. Am J Transplant. 2005 Mar; 5(3):544-8.
    View in: PubMed
    Score: 0.187
  21. Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clin Infect Dis. 2024 Sep 26; 79(3):787-794.
    View in: PubMed
    Score: 0.181
  22. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J Infect Dis. 2024 Feb 14; 229(2):413-421.
    View in: PubMed
    Score: 0.174
  23. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre-emptive monitoring in the era of letermovir. Transpl Infect Dis. 2023 Nov; 25 Suppl 1:e14171.
    View in: PubMed
    Score: 0.170
  24. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clin Infect Dis. 2022 09 10; 75(4):690-701.
    View in: PubMed
    Score: 0.157
  25. Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. Clin Microbiol Infect. 2022 Oct; 28(10):1335-1344.
    View in: PubMed
    Score: 0.155
  26. American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus Infection and Disease After Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 09; 27(9):707-719.
    View in: PubMed
    Score: 0.147
  27. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 06 10; 137(23):3291-3305.
    View in: PubMed
    Score: 0.144
  28. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol. 2021 06; 93(6):3786-3794.
    View in: PubMed
    Score: 0.138
  29. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis. 2020 04 10; 70(8):1525-1533.
    View in: PubMed
    Score: 0.133
  30. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob Agents Chemother. 2020 03 24; 64(4).
    View in: PubMed
    Score: 0.133
  31. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020 06; 20(6):1703-1711.
    View in: PubMed
    Score: 0.131
  32. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019 05; 67(2):51-55.
    View in: PubMed
    Score: 0.122
  33. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.
    View in: PubMed
    Score: 0.120
  34. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.
    View in: PubMed
    Score: 0.113
  35. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 02; 24(2):353-358.
    View in: PubMed
    Score: 0.112
  36. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. Ann Intern Med. 2015 Jan 06; 162(1):1-10.
    View in: PubMed
    Score: 0.092
  37. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med. 2014 May 08; 370(19):1781-9.
    View in: PubMed
    Score: 0.088
  38. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. 2014 Aug; 20(4):257-62.
    View in: PubMed
    Score: 0.084
  39. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011 Apr; 11(4):284-92.
    View in: PubMed
    Score: 0.071
  40. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008 Jun 01; 111(11):5403-10.
    View in: PubMed
    Score: 0.057
  41. Viral infection or reactivation in patients during treatment with dasatinib: a call for screening? Leuk Lymphoma. 2007 Dec; 48(12):2308-9.
    View in: PubMed
    Score: 0.057
  42. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007 Jul; 40(2):125-36.
    View in: PubMed
    Score: 0.055
  43. Correlation between viral loads of cytomegalovirus in blood and bronchoalveolar lavage specimens from lung transplant recipients determined by histology and immunohistochemistry. J Clin Microbiol. 2004 May; 42(5):2168-72.
    View in: PubMed
    Score: 0.044
  44. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant. 2010 Feb; 45(2):339-47.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.